新興藥物：全球市場

本報告檢視了新興藥物的全球市場，概述了當前市場狀況、市場影響因素分析、技術趨勢、法律制度、市場規模趨勢和預測、按各個細分市場和地區進行的詳細分析、競爭格局以及主要企業的概況。

目錄

第1章：摘要整理

• 市場展望
• 調查範圍
• 市場概況
• 概述
• 當前市場狀況
• 細分市場分析
• 區域分析
• 新興技術
• 結論

第2章 市場概覽

• 概述
• 宏觀經濟因素
• 波特五力分析

第3章 市場動態

• 市場動態
• 市場促進因素
• 加速監管和支持創新的框架
• 慢性病負擔日益加重和人口老化
• 加大對研發和永續資本形成的投入
• 市場限制因素
• 製造複雜性與供應鏈挑戰
• 定價和贖回方面的壓力，市場進入和收入實現方面的限制。
• 市場機遇
• 人們越來越關注罕見疾病和孤兒藥的研發
• 先進治療方法的進展：細胞療法、基因療法、RNA療法

第4章 監管情勢

• 概述
• 美國
• 歐洲
• 亞太地區

第5章：新興科技與發展

• 重點
• 下一代治療模式與平台技術
• 人工智慧主導的藥物發現與臨床開發最佳化
• 精準醫療、生物標記、伴隨診斷
• 先進的製造技術和可擴展的生產技術

第6章 市場區隔分析

• 細分市場
• 市場分析：依分子類型分類
• 重點
• 小分子藥物
• 生物製藥和生物相似藥
• 其他
• 市場分析：依產品類型
• 重點
• 原藥
• 學名藥
• 市場分析：按治療應用分類
• 重點
• 瘤
• 免疫
• 心血管系統
• 其他
• 市場分析：依最終用戶分類
• 重點
• 醫院和專科診所
• 藥局
• 其他
• 按地區分類
• 市場分析：按地區分類
• 重點
• 北美洲
• 歐洲
• 亞太地區
• 其他地區

第7章 競爭訊息

• 重點
• 競爭分析
• 策略舉措
• M&A
• 合作

第8章附錄

• 調查方法
• 資訊來源
• 簡稱
• 公司簡介
• AMGEN INC.
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON
• LILLY USA LLC.
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• VERTEX PHARMACEUTICALS INC.

The report provides an overview of the global emerging drugs and analyzes market trends, segmented by molecule type, product type, therapeutic application, and end user. It includes global revenue for the base year of 2024 and estimated data for the forecast period 2025 through 2030. The report focuses on trends, challenges, and the competitive landscape, including market share of leading companies and company profiles with financials, product portfolios, and recent developments.

Report Scope

The report analyzes the trends in the global emerging drugs market. It includes global revenue ($ billions) for the base year of 2024 and estimated data for the forecast period 2025 through 2030. The market is segmented by molecule type (small molecules, biologics and biosimilars, other molecule types), by product type (branded drugs and generic drugs), by therapeutic application (oncology, immunology, cardiovascular, other therapeutic applications), and by end users (hospitals and specialty clinics, pharmacies, and other end users). The regions covered in this study are North America, Europe, Asia-Pacific, and the rest of the World (RoW), with market analysis.

The report focuses on the trends and challenges that affect the market. It includes an analysis of the competitive landscape, with the ranking of leading companies. It offers company profiles that cover financials, product portfolios, and recent developments.

Report Includes

• An overview and analysis of the global emerging drugs market
• Analyses of global market trends, with revenue data for 2024, estimates for 2025, and projections of CAGRs through 2030
• Estimates of the current market size and revenue growth prospects, accompanied by a market share analysis by molecule type, product type, therapeutic application, end user, and region
• Facts and figures pertaining to market dynamics, including key drivers, restraints, challenges, opportunities, and the impact of macroeconomic factors
• Insights derived from Porter's Five Forces analysis, along with an assessment of market structure and competitive intensity
• Review of the regulatory landscape and approval pathways influencing the development and commercialization of emerging drugs
• Discussion of emerging technologies and developments, including advancements in small molecules, biologics, biosimilars, and cell and gene therapies
• Patent review highlighting key granted and published patents related to emerging drug development
• Analysis of the competitive landscape, including company market share rankings, strategic initiatives, and venture funding activity
• Overview of sustainability trends and ESG developments in the global emerging drugs market
• Company profiles of the leading players

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Overview
• Current Market Scenario
• Segmental Analysis
• Regional Analysis
• Emerging Technologies
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factors
• Porter's Five Forces Analysis

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Regulatory Acceleration and Supportive Innovation Pathways
• Rising Burden of Chronic Diseases and Ageing Population
• Increasing R&D Investment and Sustained Capital Formation
• Market Restraints
• Complexity of Manufacturing and Supply Chain Challenges
• Pricing and Reimbursement Pressures, Limiting Market Access and Revenue Realization
• Market Opportunities
• Increasing Focus on Rare Diseases and Orphan Drug Development
• Growth of Advanced Modalities: Cell, Gene, and RNA Therapies

Chapter 4 Regulatory Landscape

• Overview
• U.S.
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologiesand Developments

• Key Takeaways
• Next-Generation Therapeutic Modalities and Platform Technologies
• Artificial Intelligence (AI)-Driven Drug Discovery and Clinical Development Optimization
• Precision Medicine, Biomarkers, and Companion Diagnostics
• Advanced Manufacturing and Scalable Production Technologies

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis by Molecule Type
• Key Takeaways
• Small Molecules
• Biologics and Biosimilars
• Other Molecule Types
• Market Analysis by Product Type
• Key Takeaways
• Branded Drugs
• Generic Drugs
• Market Analysis by Therapeutic Application
• Key Takeaways
• Oncology
• Immunology
• Cardiovascular
• Other Therapeutic Applications
• Market Analysis by End User
• Key Takeaways
• Hospitals and Specialty Clinics
• Pharmacies
• Other End Users
• Geographic Breakdown
• Market Analysis by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Analysis
• Strategic Initiatives
• Mergers and Acquisitions
• Collaborations

Chapter 8 Appendix

• Research Methodology
• Sources
• Abbreviations
• Company Profiles
• AMGEN INC.
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON
• LILLY USA LLC.
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• VERTEX PHARMACEUTICALS INC.

List of Tables

• Summary Table : Global Market for Emerging Drugs, by Region, Through 2030
• Table 1 : Global Market for Emerging Drugs, by Molecule Type, Through 2030
• Table 2 : Global Market for Emerging Small Molecules Drugs, by Region, Through 2030
• Table 3 : Global Market for Emerging Biologics and Biosimilars Drugs, by Region, Through 2030
• Table 4 : Global Market for Emerging Other Molecule Types Drugs, by Region, Through 2030
• Table 5 : Global Market for Emerging Drugs, by Product Type, Through 2030
• Table 6 : Global Market for Emerging Branded Drugs, by Region, Through 2030
• Table 7 : Global Market for Emerging Generic Drugs, by Region, Through 2030
• Table 8 : Global Market for Emerging Drugs, by Therapeutic Application, Through 2030
• Table 9 : Global Market for Emerging Oncology Drugs, by Region, Through 2030
• Table 10 : Global Market for Emerging Immunology Drugs, by Region, Through 2030
• Table 11 : Global Market for Emerging Cardiovascular Drugs, by Region, Through 2030
• Table 12 : Global Market for Other Emerging Therapeutic Applications Drugs, by Region, Through 2030
• Table 13 : Global Market for Emerging Drugs, by End User, Through 2030
• Table 14 : Global Market for Emerging Drugs for Hospitals and Specialty Clinics, by Region, Through 2030
• Table 15 : Global Market for Emerging Drugs for Pharmacies, by Region, Through 2030
• Table 16 : Global Market for Emerging Drugs for Other End Users, by Region, Through 2030
• Table 17 : Global Market for Emerging Drugs , by Region, Through 2030
• Table 18 : North American Market for Emerging Drugs, by Molecule Type, Through 2030
• Table 19 : North American Market for Emerging Drugs, by Product Type, Through 2030
• Table 20 : North American Market for Emerging Drugs, by Therapeutic Application, Through 2030
• Table 21 : North American Market for Emerging Drugs, by End User, Through 2030
• Table 22 : European Market for Emerging Drugs, by Molecule Type, Through 2030
• Table 23 : European Market for Emerging Drugs, by Product Type, Through 2030
• Table 24 : European Market for Emerging Drugs, by Therapeutic Application, Through 2030
• Table 25 : European Market for Emerging Drugs, by End User, Through 2030
• Table 26 : Asia-Pacific Market for Emerging Drugs, by Molecule Type, Through 2030
• Table 27 : Asia-Pacific Market for Emerging Drugs, by Product Type, Through 2030
• Table 28 : Asia-Pacific Market for Emerging Drugs, by Therapeutic Application, Through 2030
• Table 29 : Asia-Pacific Market for Emerging Drugs, by End User, Through 2030
• Table 30 : RoW Market for Emerging Drugs, by Molecule Type, Through 2030
• Table 31 : RoW Market for Emerging Drugs, by Product Type, Through 2030
• Table 32 : RoW Market for Emerging Drugs, by Therapeutic Application, Through 2030
• Table 33 : RoW Market for Emerging Drugs, by End User, Through 2030
• Table 34 : Global Ranking of Companies in Emerging Drugs Market, 2024
• Table 35 : Mergers and Acquisitions in Global Emerging Drugs Market, 2023-2026
• Table 36 : Collaborations in Global Emerging Drugs Market, 2023-2025
• Table 37 : Information Sources Used for this Report
• Table 38 : Abbreviations Used in this Report
• Table 39 : Amgen Inc.: Company Snapshot
• Table 40 : Amgen Inc.: Financial Performance, FY 2023 and 2024
• Table 41 : Amgen Inc.: Product Portfolio
• Table 42 : Amgen Inc.: News/Key Developments, 2023-2026
• Table 43 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 44 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
• Table 45 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 46 : Bristol-Myers Squibb Co.: News/Key Developments, 2024 and 2025
• Table 47 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 48 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 49 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 50 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023-2025
• Table 51 : Johnson & Johnson: Company Snapshot
• Table 52 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
• Table 53 : Johnson & Johnson: Product Portfolio
• Table 54 : Johnson & Johnson: News/Key Developments, 2023-2026
• Table 55 : Lilly USA LLC.: Company Snapshot
• Table 56 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
• Table 57 : Lilly USA LLC.: Product Portfolio
• Table 58 : Lilly USA LLC.: News/Key Developments, 2024-2026
• Table 59 : Merck & Co. Inc.: Company Snapshot
• Table 60 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
• Table 61 : Merck & Co. Inc.: Product Portfolio
• Table 62 : Merck & Co. Inc.: News/Key Developments, 2023-2025
• Table 63 : Novartis AG: Company Snapshot
• Table 64 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 65 : Novartis AG: Product Portfolio
• Table 66 : Novartis AG: News/Key Developments, 2024-2026
• Table 67 : Pfizer Inc.: Company Snapshot
• Table 68 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
• Table 69 : Pfizer Inc.: Product Portfolio
• Table 70 : Pfizer Inc.: News/Key Developments, 2023-2025
• Table 71 : Regeneron Pharmaceuticals Inc.: Company Snapshot
• Table 72 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 73 : Regeneron Pharmaceuticals Inc.: Product Portfolio
• Table 74 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2025
• Table 75 : Vertex Pharmaceuticals Inc.: Company Snapshot
• Table 76 : Vertex Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 77 : Vertex Pharmaceuticals Inc.: Product Portfolio
• Table 78 : Vertex Pharmaceuticals Inc.: News/Key Developments, 2025

List of Figures

• Summary Figure : Global Market Shares for Emerging Drugs, by Region, 2024
• Figure 1 : Porter's Five Forces Analysis of the Global Emerging Drugs Market
• Figure 2 : Market Dynamics of Emerging Drugs
• Figure 3 : Global Market Shares for Emerging Drugs, by Molecule Type, 2024
• Figure 4 : Global Market Shares for Emerging Drugs, by Product Type, 2024
• Figure 5 : Global Market Shares for Emerging Drugs, by Therapeutic Application, 2024
• Figure 6 : Global Market Shares for Emerging Drugs, by End User, 2024
• Figure 7 : Global Market Shares for Emerging Drugs, by Region, 2024
• Figure 8 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 9 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 10 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
• Figure 11 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
• Figure 12 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
• Figure 13 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
• Figure 14 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
• Figure 15 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
• Figure 16 : Lilly USA LLC.: Revenue Shares, by Business Unit, FY 2024
• Figure 17 : Lilly USA LLC.: Revenue Shares, by Country/Region, FY 2024
• Figure 18 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 19 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 20 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
• Figure 21 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
• Figure 22 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 23 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 24 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 25 : Vertex Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024